carmustine has been researched along with Myeloproliferative Disorders in 2 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sawada, T | 1 |
| Adachi, Y | 1 |
| Ishii, Y | 1 |
| Yasui, H | 1 |
| Arimura, Y | 1 |
| Endo, T | 1 |
| Caballero, MD | 1 |
| Amigo, ML | 1 |
| Hernández, JM | 1 |
| Vazquez, L | 1 |
| del Cañizo, C | 1 |
| Gonzalez, M | 1 |
| García, R | 1 |
| San Miguel, JF | 1 |
2 other studies available for carmustine and Myeloproliferative Disorders
| Article | Year |
|---|---|
Esophageal lesions in myeloproliferative neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Esophageal Neopl | 2012 |
Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etop | 1997 |